Neuberger Berman Group
TCRX icon

Neuberger Berman Group’s TScan Therapeutics TCRX Stock Holding History

Neuberger Berman Group’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-18,400
Closed -$18.4K – 2249
2025
Q4 		$18.4K Hold
18,400
– – ﹤0.01% 2095
2025
Q3 		$33.5K Sell
18,400
-2,767
-13% -$4.9K ﹤0.01% 2008
2025
Q2 		$30.7K Buy
+21,167
New +$30.6K ﹤0.01% 2004

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Neuberger Berman Group's TCRX Position: Q1 2026 in Review

Neuberger Berman Group sold out of TScan Therapeutics (TCRX) in Q1 2026, closing a stake of 18,400 shares — an estimated $18.4K sold.

Neuberger Berman Group first reported a position in TCRX in Q2 2025 and held it in 3 quarters. The position peaked at $33.5K in Q3 2025. 60 funds tracked by Wall St. Rank hold TCRX as of Q1 2026.

  • Neuberger Berman Group reported no remaining TScan Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Neuberger Berman Group sold 18,400 TScan Therapeutics shares in Q1 2026, an estimated $18.4K.
  • Neuberger Berman Group first reported a position in TScan Therapeutics in Q2 2025 and held it in 3 quarters.
  • Neuberger Berman Group's TScan Therapeutics position peaked at $33.5K in Q3 2025.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2026.

Based on Neuberger Berman Group's 13F filing for Q1 2026, filed 14 May 2026.